Journal article

Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews

Paul K Nelson, Bradley M Mathers, Benjamin Cowie, Holly Hagan, Don Des Jarlais, Danielle Horyniak, Louisa Degenhardt

The Lancet | ELSEVIER SCIENCE INC | Published : 2011


Awarded by Reckitt Benckiser in Australia

Awarded by US National Institute on Drug Abuse

Awarded by US National Institutes of Health

Funding Acknowledgements

LD and BMM have received grant money and have acted as independent consultants to WHO, the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the United Nations Office on Drugs and Crime (UNODC). DO) has been funded by and consulted for WHO. LD received an untied educational grant (2006-08) from Reckitt Benckiser in Australia to do a postmarketing surveillance study of buprenorphine-naloxone for the treatment of heroin dependence in Australia.This report received funding support from WHO's HIV department and the Australian National Drug and Alcohol Research Centre, which receives funding from the Australian Department of Health and Ageing. The HCV Synthesis Project was funded by US National Institute on Drug Abuse Grant R01 DA018609. DDJ is supported by US National Institutes of Health grant DA003574. LD is supported by an Australian National Health and Medical Research Council Senior Research Fellowship. PKN and DH are supported by Australian Postgraduate Awards. This study was completed as part of the work of the 2010 Global Burden of Disease (GBD) Illicit Drugs expert group. The work of the Reference Group to the UN on HIV and Injecting Drug Use in 2007 was undertaken by the Secretariat, based at the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales (UNSW; Sydney, Australia). We thank the GBD team from the NDARC (Bianca Calabria, Chiara Bucello, and Anna Roberts, who contributed to earlier phases of the work and Mary Kumvaj and Eva Congreve who assisted with the compilation of the literature); Paul McElwee (Burnet Institute, Melbourne, VIC, Australia) for assistance with data extraction; Benjamin Phillips (NDARC) for his work on the systematic review of HIV and injecting drug use and his assistance with generation of maps; the many local and international experts who assisted with compilation of data, provided further data, commented on estimates, or provided support during the data collection process; the European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) for the data published online, submitted by their network of Focal Points across the EU; Maria Elena Medina-Mora (National Institute on Psychiatry Ramon de la Fuente Muniz, Mexico) for sourcing and translation efforts; Khayriyyah Mohd Hanafiah (Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA); Steven Wiersma (WHO, Geneva, Switzerland) for advice on hepatitis epidemiology and early results from the GBD hepatitis expert group; and Annette Verster (WHO, Geneva, Switzerland) for financial support of part of this review. Contributors of data and advice on this review are listed fully at